Gilead Sciences faces no challenges against coronavirus
Gilead Sciences, Inc.(GILD) currently trades at $73.89 and has grown by 4.71% in the past 24 hours. Gilead Sciences created the antiviral drug, Remdesivir, as a possible treatment for Ebola and the Marburg virus. It has since been found to be potentially effective in treating COVID-19, the disease caused by the novel coronavirus. Some investors think this could mean significant revenue in the near term for Gilead, and the stock is up 10% so far this year.
Based on this information, investorsQ rates this stock an 6 out of 10. We give it this rating because ever since the coronavirus pandemic began in the middle of February, Remdesivir has dominated the news and discussion regarding Gilead’s future. The high forecast for Gilead Sciences, Inc. is $90 and the low is $58. Notably, the company’s market cap is $93.35 with a 52 week high of $85.97 and a 52 week low of $60.89.